Compare WTBA & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTBA | EVMN |
|---|---|---|
| Founded | 1893 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.4M | 405.2M |
| IPO Year | 2002 | 2025 |
| Metric | WTBA | EVMN |
|---|---|---|
| Price | $28.77 | $14.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $24.00 | ★ $43.88 |
| AVG Volume (30 Days) | 61.0K | ★ 472.8K |
| Earning Date | 04-23-2026 | 06-11-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | 35.21 | ★ 75.23 |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | $23.80 | N/A |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $23.13 | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $18.81 | $10.47 |
| 52 Week High | $30.33 | $33.20 |
| Indicator | WTBA | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 56.37 |
| Support Level | $25.77 | $13.89 |
| Resistance Level | $28.80 | $21.21 |
| Average True Range (ATR) | 0.66 | 0.71 |
| MACD | -0.03 | 0.40 |
| Stochastic Oscillator | 39.49 | 90.14 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings, and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.